Metastic Melanoma

Caladrius Biosciences Inc (NASDAQ: CLBS), a penny-stock clinical-stage biopharmaceutical company announced after Wednesday's market close it will discontinue an ongoing Phase 3 study. Shares of Caladrius Biosciences plunged nearly 40 percent following the announcement. Caladrius...